Welcome to visit Zhongnan Medical Journal Press Series journal website!

Home Articles Vol 27,2024 No.4 Detail

Study on the curcumin-loaded mesoporous silica nanoparticles modified by polydopamine

Published on May. 06, 2024Total Views: 383 times Total Downloads: 208 times Download Mobile

Author: WANG Xiaoning REN Peipei ZHAO Yangguang ZHANG Zhanrui YAN Mengru

Affiliation: School of Pharmacy, Xian Medical University, Xian 710021, China

Keywords: Mesoporous silica Polydopamine Curcumin Triple negative breast cancer pH responsive

DOI: 10.12173/j.issn.1008-049X.202312188

Reference: WANG Xiaoning, REN Peipei, ZHAO Yangguang, ZHANG Zhanrui, YAN Mengru.Study on the curcumin-loaded mesoporous silica nanoparticles modified by polydopamine[J].Zhongguo Yaoshi Zazhi,2024, 24(4):580-587.DOI: 10.12173/j.issn.1008-049X.202312188.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Objective  To prepare curcumin-loaded (CUR) mesoporous silica nanoparticles (MSN) modified by polydopamine (PDA), and study their pharmaceutical properties, drug release in vitro and antitumor activity in vitro.

Methods  Mesoporous silica nanoparticles were synthesized by template method and modified with PDA. The pharmaceutical properties of the nanoparticles were investigated. The responsive release of drug-loaded preparations at different pH was studied. The biocompatibility of the carrier and the inhibition rate of cell growth in vitro of the drug-loaded preparations were evaluated. The uptake of the drug-loaded preparations by tumor cells was examined.

Results  The particle size of MSN was uniform. After the PDA modification, the drug release rate of CUR@MSN-PDA was significantly dependent on pH. The results of biocompatibility experiments showed that, the cell survival rate was above 85% after co-cultured with MDA-MB-231 cells for 24 h. The results of in vitro tumor cell growth inhibition test showed that, the growth inhibition rate of CUR@MSN-PDA on tumor cells was significantly higher than that of CUR@MSN. The results of cell uptake showed that the fluorescent strength of CUR@MSN-PDA in the cell was significantly stronger than that of the CUR@MSN.

Conclusion  The nano-carrier constructed has significant pH response and enhanced anti-tumor activity, which can provide a theoretical basis for the drug delivery of CUR.

Full-text
Please download the PDF version to read the full text: download
References

1.刘宗易, 彭明利. 姜黄素类化合物的研究进展[J]. 药学研究, 2022, 41(10): 673-677. [Liu ZY, Peng  ML. Research progress of curcuminoids[J]. Journal of Pharmaceutical Research, 2022, 41(10): 673-677.] DOI: 10.13506/j.cnki.jpr. 2022.10.009.

2.崔明花, 付二花, 林贞花, 等. 姜黄素抗肿瘤药理作用的研究进展[J]. 中国临床药理学杂志, 2021, 37(2): 186-188, 196. [Cui MH, Fu EH, Lin ZH, et al. Research progress of pharmacological functions on tumor suppression by curcumin[J]. The Chinese Journal of Clinical Pharmacology, 2021, 37(2): 186-188, 196.] DOI: 10.13699/j.cnki.1001-6821.2021.02.022.

3.严德康, 张新悦, 王宇佳, 等. 甘露糖修饰姜黄素 /人参皂苷Rb1脂质体的处方优选及体外脑靶向性评价[J]. 中国药师, 2022, 25(1): 11-17. [Yan DK, Zhang XY, Wang YJ, et al. Formulation optimization and invitro brain targeting evaluation of mannose-modified curcumin/ginsenoside Rb1 liposomes[J]. China Pharmacist, 2022, 25(1): 11-17. DOI: 10.19962/j.cnki.issn1008-049X.2022.01.003.

4.王莉娟, 张国霞, 刘海龙, 等. 姜黄素抗肿瘤作用及其作用机制研究进展[J]. 甘肃中医药大学学报, 2022, 39(5): 78-82. [Wang LJ, Zhang GX, Liu HL, et al. Recent advances in the study of curcumin's anti-tumor effects and mechanisms[J]. Journal of Gansu University of Chinese Medicine, 2022, 39(5): 78-82.] DOI: 10.16841/j.issn1003-8450.2022.05.17.

5.刘婷, 高飞云, 张转红, 等. 姜黄素抗结肠癌作用机制的研究进展[J].中草药, 2022, 53(24): 7933-7940. [Liu T, Gao FY, Zhang ZH, et al. Research progress on mechanism of curcumin against colon cancer[J]. Chinese Traditional and Herbal Drugs, 2022, 53(24): 7933-7940.] DOI: 10.7501/j.issn.0253-2670.2022.24.031.

6.Tsuda T. Curcumin as a functional food-derived factor: degradation products, metabolites, bioactivity, and future perspectives[J]. Food Funct, 2018, 9(2): 705-714. DOI: 10.1039/c7fo01242j.

7.李艳梅, 张宇佳, 陈明曦, 等. 介孔二氧化硅纳米粒作为药物载体研究进展[J]. 中国药剂学杂志, 2021, 19(2): 52-59. [Li YM, Zhang YJ, Chen MX, et al. Progress research of mesoporous silica nanoparticles as drug carriers[J]. Chinese Journal of Pharmaceutics, 2021, 19(2): 52-59.] DOI: 10.14146/j.cnki.cjp.2021.02.003.

8.王彦竹, 孙立章, 宋爱华, 等. 介孔二氧化硅纳米粒的制备及对载药与药物溶出度的影响[J]. 沈阳药科大学学报, 2012, 29(4): 258-263. [Wang YZ, Sun LZ, Song AH, et al. Synthesis of mesoprous silica nanoparticle and the effect on drug loading and dissolution[J]. Journal of Shenyang Pharmaceutical University, 2012, 29(4): 258-263.] DOI: 10.14066/j.cnki.cn21-1349/r.2012.04.009.

9.Chen LG, Fu C, Deng YJ, et al. A pH-sensitive nanocarrier for tumor targeting[J]. Pharm Res, 2016, 33(12): 2989-2998. DOI: 10.1007/s11095-016-2021-2.

10.Tian YF, Lei M. Polydopamine-based composite nanoparticles with redox-labile polymer shells for controlled drug release and enhanced chemo-photothermal therapy[J]. Nanoscale Res Lett, 2019, 14(1): 186. DOI: 10.1186/s11671-019-3027-6.

11.Zhao RR, Li T, Zheng GR, et al. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co- delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex[J]. Biomaterials, 2017, 143(2): 1-16. DOI: 10.1016/j.biomaterials.2017.07.030.

12.赵晨旭, 左芳, 潘丽, 等. 聚多巴胺功能化纳米银粒子制备及抗菌性能[J]. 精细化工, 2014, 31(5): 545-550. [Zhao CX, Zuo F, Pan L, et al. Preparation and antibacterial properties of polydopamine functionalized Ag nanoparticles[J]. Fine Chemicals, 2014, 31(5): 545-550.] DOI: 10.13550/j.jxhg.2014.111.

13.刘宗光, 屈树新, 翁杰. 聚多巴胺在生物材料表面改性中的应用[J]. 化学进展, 2015, 27(Z1): 212-219. [Liu ZG, Qu SX, Weng J. Application of polydopamine in surface modification of biomaterials[J]. Progress in Chemistry, 2015, 27(Z1): 212-219.] DOI: 10.7536/PC140921.

14.Chen H, Xie LQ, Qin J, et al. Surface modification of PLGA nanoparticles with biotinylated chitosan for the sustained in vitro release and the enhanced cytotoxicity of epirubicin[J]. Colloids Surf B Biointerfaces, 2016, 138: 1-9. DOI: 10.1016/j.colsurfb.2015.11.033.

15.吕晓洁, 董玉. 介孔二氧化硅用于口服药物增溶的研究进展[J]. 中南药学, 2021, 19(3): 492-500. [Lyu XJ, Dong Y. Research progress in mesoporous silica for oral drug solubilization[J]. Central South Pharmacy, 2021, 19(3): 492-500.] DOI: 10.7539/j.issn.1672-2981.2021. 03.021.

16.李玉芬, 王东凯. 聚多巴胺在肿瘤纳米药物递送中的应用[J]. 中国药剂学杂志, 2021, 19(3): 81-86. [Li YF, Wang DK. Application of polydopamine in tumor nano-drug delivery[J]. Chinese Journal of Pharmaceutics, 2021, 19(3): 81-86.] DOI: 10.14146/j.cnki.cjp.2021.03.003.

Popular papers
Last 6 months